Gaps and barriers in the control of blood glucose in people with type 2 diabetes.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
metformin 13 endocrinologydiseasesdrugs
obesity 1 endocrinologydiseases
pioglitazone 1 endocrinologydiseasesdrugs
type 1 diabetes mellitus 2 endocrinologydiseases
type 2 diabetes mellitus 4 endocrinologydiseases
Insulin 1 endocrinologydiseasesdrugs
diabetes mellitus 6 endocrinologydiseases
glyburide 1 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Insulin 33559 initiation was also more likely in patients who were younger, had diabetes-related complications or smoked. Insulin -treated patients were more likely to be adherent, and there was no apparent deterioration in quality
glyburide 37719 continuing metformin plus insulin therapy or triple oral glucose–lowering therapy with metformin, glyburide and pioglitazone. Good glycaemic control was maintained for over 6 years with no significant difference
metformin 36687 insulin.[60][61][32][63][64]–[65] The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study compared metformin alone, metformin plus a thiazolidinedione and metformin plus intensive lifestyle intervention as initial
metformin 36704 Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study compared metformin alone, metformin plus a thiazolidinedione and metformin plus intensive lifestyle intervention as initial therapy for
metformin 36743 Adolescents and Youth (TODAY) study compared metformin alone, metformin plus a thiazolidinedione and metformin plus intensive lifestyle intervention as initial therapy for new-onset T2DM in people aged 10–17 years
metformin 37025 glycaemic control over 5 years was significantly higher with the combination pharmacotherapy than either metformin alone or metformin plus intensive lifestyle measures. The combination pharmacotherapy was also associated
metformin 37044 5 years was significantly higher with the combination pharmacotherapy than either metformin alone or metformin plus intensive lifestyle measures. The combination pharmacotherapy was also associated with greater
metformin 37561 (mean age = 45 years) people with newly diagnosed T2DM who started treatment for 3 months with metformin plus insulin and were then randomized to either continuing metformin plus insulin therapy or triple
metformin 37630 treatment for 3 months with metformin plus insulin and were then randomized to either continuing metformin plus insulin therapy or triple oral glucose–lowering therapy with metformin, glyburide and pioglitazone.
metformin 37708 to either continuing metformin plus insulin therapy or triple oral glucose–lowering therapy with metformin , glyburide and pioglitazone. Good glycaemic control was maintained for over 6 years with no significant
metformin 37889 over 6 years with no significant difference between the groups (end of study HbA1c = 7.3% for metformin plus insulin and 6.4 for triple oral combination; p = 0.4).[62]A review of the health records for
metformin 38082 health records for nearly 3000 people with T2DM in the United States found that early initiation of metformin (within 6 months of diagnosis) significantly reduced HbA1c (−0.36%; p < 0.001) and BMI (−0.46 kg/m2;
metformin 38276 p < 0.001) and BMI (−0.46 kg/m2; p < 0.001) compared with when introduction of pharmacotherapy with metformin was delayed. The likelihood of achieving HbA1c ≤ 7% was doubled and the likelihood of requiring
metformin 38471 likelihood of requiring therapy intensification was reduced by 28% with early versus delayed initiation of metformin .[63] Another study in the United States looking at medical records for 5870 people with T2DM found a
metformin 38740 glucose–lowering therapy. Early intensification was defined as addition of a second oral drug to metformin therapy within 3 months of treatment failure (HbA1c ≥ 7.5%) and late intensification as the
pioglitazone 37733 metformin plus insulin therapy or triple oral glucose–lowering therapy with metformin, glyburide and pioglitazone . Good glycaemic control was maintained for over 6 years with no significant difference between the
Select Disease Character Offset Disease Term Instance
diabetes mellitus 2665 of early and intensive control of blood glucose levels in improving outcomes for people with type 2 diabetes mellitus (T2DM) was established in the UK Prospective Diabetes Study (UKPDS).[1] Despite differences in glucose
diabetes mellitus 8226 Social Care Information Centre (HSCIC)[31]USA1373T1DM or T2DM35Laiteerapong et al.[32]TIDM: type 1 diabetes mellitus ; T2DM: type 2 diabetes mellitus.aTarget HbA1c ≤ 7.0% (≤53 mmol/mol), other than for the study
diabetes mellitus 8258 (HSCIC)[31]USA1373T1DM or T2DM35Laiteerapong et al.[32]TIDM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus .aTarget HbA1c ≤ 7.0% (≤53 mmol/mol), other than for the study of Laiteerapong et al. which
diabetes mellitus 16594 how to intensify therapy for patients not reaching glycaemic goals.Williamson et al.[48]TIDM: type 1 diabetes mellitus ; T2DM: type 2 diabetes mellitus; HCPs: healthcare professionals.Patient-level barriersPrescribers often
diabetes mellitus 16626 patients not reaching glycaemic goals.Williamson et al.[48]TIDM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus ; HCPs: healthcare professionals.Patient-level barriersPrescribers often identify poor patient motivation
diabetes mellitus 29938 with patient self-management (43%).Ratanawongsa et al.[59]LDL: low-density lipoprotein; T2DM: type 2 diabetes mellitus ; HCPs: healthcare professionals.A number of studies have attempted to explore the factors that may act
obesity 36869 lifestyle intervention as initial therapy for new-onset T2DM in people aged 10–17 years and with obesity . The proportion of people who maintained glycaemic control over 5 years was significantly higher with
type 1 diabetes mellitus 8219 Health and Social Care Information Centre (HSCIC)[31]USA1373T1DM or T2DM35Laiteerapong et al.[32]TIDM: type 1 diabetes mellitus ; T2DM: type 2 diabetes mellitus.aTarget HbA1c ≤ 7.0% (≤53 mmol/mol), other than for the study
type 1 diabetes mellitus 16587 guidelines and how to intensify therapy for patients not reaching glycaemic goals.Williamson et al.[48]TIDM: type 1 diabetes mellitus ; T2DM: type 2 diabetes mellitus; HCPs: healthcare professionals.Patient-level barriersPrescribers often
type 2 diabetes mellitus 2658 importance of early and intensive control of blood glucose levels in improving outcomes for people with type 2 diabetes mellitus (T2DM) was established in the UK Prospective Diabetes Study (UKPDS).[1] Despite differences in glucose
type 2 diabetes mellitus 8251 Centre (HSCIC)[31]USA1373T1DM or T2DM35Laiteerapong et al.[32]TIDM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus .aTarget HbA1c ≤ 7.0% (≤53 mmol/mol), other than for the study of Laiteerapong et al. which
type 2 diabetes mellitus 16619 for patients not reaching glycaemic goals.Williamson et al.[48]TIDM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus ; HCPs: healthcare professionals.Patient-level barriersPrescribers often identify poor patient motivation
type 2 diabetes mellitus 29931 problems with patient self-management (43%).Ratanawongsa et al.[59]LDL: low-density lipoprotein; T2DM: type 2 diabetes mellitus ; HCPs: healthcare professionals.A number of studies have attempted to explore the factors that may act

You must be authorized to submit a review.